Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Peter M K de Blank"'
Autor:
Peter M K de Blank, Andrea M Gross, Srivandana Akshintala, Jaishri O Blakeley, Gideon Bollag, Ashley Cannon, Eva Dombi, Jason Fangusaro, Bruce D Gelb, Darren Hargrave, AeRang Kim, Laura J Klesse, Mignon Loh, Staci Martin, Christopher Moertel, Roger Packer, Jonathan M Payne, Katherine A Rauen, Jonathan J Rios, Nathan Robison, Elizabeth K Schorry, Kevin Shannon, David A Stevenson, Elliot Stieglitz, Nicole J Ullrich, Karin S Walsh, Brian D Weiss, Pamela L Wolters, Kaleb Yohay, Marielle E Yohe, Brigitte C Widemann, Michael J Fisher
Publikováno v:
Neuro Oncol
Neuro-Oncology, vol 24, iss 11
Neuro-Oncology, vol 24, iss 11
The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent
Autor:
Andrew T. Trout, Robin E. Norris, Peter M. K. de Blank, Lori R. Backus, Alexander J. Towbin, Jaylynn M. Nash
Publikováno v:
Pediatric Blood & Cancer.
Autor:
Peter M K de Blank, Katharine R Lange, Mengqi Xing, Sedigheh Mirzaei Salehabadi, Deokumar Srivatava, Tara M Brinkman, Kirsten K Ness, Kevin C Oeffinger, Joseph Neglia, Kevin R Krull, Yutaka Yasui, Paul Nathan, Rebecca Howell, Lucie Turcotte, Wendy Leisenring, Gregory T Armstrong, Daniel C Bowers, M Fatih Okcu
Publikováno v:
Neuro-Oncology. 24:i90-i91
PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent